Key facts
- Okogen’s last known valuation is $4.9M (Dec 2024).
- It has raised $13.5M across 1 recorded rounds; the latest was Seed Round ($2.5M) in Nov 2024.
- Notable investors include Brandon Capital, Brandon Biocatalyst.
- Okogen has filed 1 Form D with the SEC, most recently Dec 2024 ($2.5M sold to 9 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Okogen
Funding rounds
1 roundsAbout Okogen
Developer of an ophthalmic specialty platform designed to treat unmet needs in ophthalmic infectious diseases. The company's platform focuses on infectious ocular diseases where treatments are either not available or unsatisfactory and provides an opportunity to address adenoviral infections of the eye as well as other classes of viruses that are active in the ocular space, enabling patients to reduce suffering, improve quality of life, and preserve vision.
- Sector
- Healthcare
- HQ
- Plano, TX, United States
- Founded
- 2015
- Employees
- 10
- Website
- okogen.com/
- Ownership
- Privately Held (backing)
Okogen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Okogen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Okogen in its N-PORT filings yet. We sweep new filings monthly.